Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
SignalChem Lifesciences, and a subsidiary of Merck, are evaluating the combination of SLC-391, a selective AXL inhibitor developed by SignalChem, with Keytruda (pembrolizumab) in patients with advanced non-small cell lung cancer.
Even with access to a clinical trial, cancer patients living in the poorest neighborhoods in America have a nearly 30% greater chance of dying from their disease compared to the wealthiest patients, SWOG Cancer Research Network study results show.
ILLUMINATE-301, the registration trial of tilsotolimod in combination with Yervoy (ipilimumab) versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, did not meet its primary endpoint of objective response rate.
Aveo Oncology and Bristol Myers Squibb are collaborating on a phase III clinical trial to evaluate Fotivda (tivozanib) in combination with Opdivo (nivolumab) in patients with advanced relapsed or refractory renal cell carcinoma following prior immunotherapy exposure.
Researchers at Johns Hopkins Kimmel Cancer Center developed a prototype for a new cancer immunotherapy that uses engineered T cells to target a genetic alteration common among all cancers.
The O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham is partnering with the GO2 Foundation for Lung Cancer in a study—together with Vanderbilt University Medical Center and Augusta University—to determine how to improve participation from Black communities in lung cancer clinical trials.
In its first clinical trial in patients with a hard-to-treat form of uterine cancer, a targeted drug that subjects tumor cells to staggering levels of DNA damage caused tumors to shrink in nearly one-third of patients, investigators at Dana-Farber Cancer Institute found.
The National Comprehensive Cancer Network has published new best practice recommendations for Management of COVID-19 infection in patients with cancer.
A comprehensive review by University of North Carolina researchers and colleagues of hundreds of publications, incorporating more than two dozen articles on prevention screening for lung cancer with low-dose spiral computed tomography, shows there are both benefits and harms from screening.
